GemPharmatech Co (SHSE:688046) Marketable Securities: ¥714.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688046 GemPharmatech Co Ltd SHSE:688046
89 GF Score
Price ¥33.00
GF Value ¥19.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is GemPharmatech Co Marketable Securities?

GemPharmatech Co SHSE:688046 -3.93% 89 Marketable Securities is ¥714.8 Mil as of Jun. 2026. GuruFocus rates SHSE:688046 with a GF Score™ of 89/100 and a GF Value™ of ¥19.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. GemPharmatech Co's Marketable Securities for the quarter that ended in Jun. 2026 was ¥714.8 Mil.

GemPharmatech Co's annual Marketable Securities declined from Dec. 2023 (¥637.7 Mil) to Dec. 2024 (¥467.3 Mil) but then increased from Dec. 2024 (¥467.3 Mil) to Dec. 2025 (¥757.7 Mil).

GemPharmatech Co  (SHSE:688046) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

GemPharmatech Co Marketable Securities Related Terms

GemPharmatech Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for GemPharmatech Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GemPharmatech Co Marketable Securities Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 205.80 791.24 637.72 467.34 757.69

GemPharmatech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 670.25 894.15 757.69 670.48 714.81
SHSE:688046
89GF Score
GemPharmatech Co Ltd SHSE:688046
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GemPharmatech Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ¥714.8 Mil mean?
GemPharmatech Co (SHSE:688046) has a Marketable Securities of ¥714.8 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on GemPharmatech Co and its competitors.
Is GemPharmatech Co's Marketable Securities too high?
GemPharmatech Co's current Marketable Securities is ¥714.8 Mil. Overall, GemPharmatech Co has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's Marketable Securities compare to VRTX and REGN?
GemPharmatech Co's Marketable Securities of ¥714.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on GemPharmatech Co and its competitors. GemPharmatech Co's current Marketable Securities is ¥714.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.15, compared to a current price of ¥33.00 — trading 72.3% above its estimated fair value. The current Marketable Securities is ¥714.8 Mil. GemPharmatech Co's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current Marketable Securities is ¥714.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?

Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued. The current stock price of ¥33.00 is trading 72.3% above its estimated GF Value™ of ¥19.15. GuruFocus considers GemPharmatech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688046:

  • Marketable Securities: ¥714.8 Mil
  • GF Value™: ¥19.15 vs. price of ¥33.00 (72.3% above fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GemPharmatech Co Business Description

Address No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
89GF Score

Get the complete analysis for SHSE:688046

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥33.00
Price
¥19.15
GF Value